Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 10 art units • 11 examiners • 0 of 13 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Korea Research Institute of Bioscience and Biotechnology has 13 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 11 distinct examiners and 10 distinct art units, showing broad distribution across examination assignments and technical groups.
MIANO, JOSEPH PAUL is the busiest examiner, with 2 pending matters. The work is not concentrated in a single examiner, so docket management should support multiple response positions while preserving consistency in related biotechnology disclosures and claim terminology.
The difference between the pending-action count and the examiner and art-unit counts indicates that some examiners and units handle multiple matters. Counsel can use those recurring assignments to identify opportunities for coordinated prior-art review, but should not assume that every matter will receive the same examination treatment.
A portfolio-level map of claim themes and unit assignments may help prioritize recurring issues. Examiner-specific preparation remains necessary because the pending work is spread across many individual prosecution relationships.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (8%) |
| §101 + other | 2 (15%) |
| §103 only | 2 (15%) |
| §102 only | 1 (8%) |
| §112 only | 2 (15%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 4 (31%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 2 | 35.7% | +63.4% |
| REYNOLDS, FRED H | 2 | 32.9% | +39.3% |
| DURYEE, ALEXANDER MARSH | 1 | 33.3% | +41.7% |
| SINGH, ANOOP KUMAR | 1 | 43.2% | +67.7% |
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.3% | +58.8% |
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
| TURPIN, ZACHARY MARK | 1 | 4.0% | -5.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | KONOPKA, CATHERINE ANNE | 7d |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | REYNOLDS, FRED H | 61d |
| 18270078 | TRANSFORMED HUMAN HEPATIC STELLATE CELL LINE AND USE THEREOF | MIANO, JOSEPH PAUL | — |
| 18837056 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | SINGH, ANOOP KUMAR | — |
| 18282160 | NOVEL BICYCLIC COMPOUND, OPTICAL ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE THEREOF, AND PREPARATION METHOD THEREFOR | REYNOLDS, FRED H | — |
| 18037222 | COMPOSITION FOR DETECTING TARGET NUCLEIC ACID AND METHOD FOR DETECTING TARGET NUCLEIC ACID USING SAME | GIAMMONA, FRANCESCA FILIPPA | — |
| 17609871 | METHOD AND COMPOSITION FOR DETECTING THYROID CANCER-SPECIFIC DNA METHYLATION BIOMARKER FOR DIAGNOSIS OF THYROID CANCER | TURPIN, ZACHARY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17767425 | MONO-HYDROXY OR DI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS, PRODUCTION METHOD THEREFOR, AND USE THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 45d overdue |
| 17231278 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME | MIANO, JOSEPH PAUL | 16d overdue |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | KONOPKA, CATHERINE ANNE | 7d |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | REYNOLDS, FRED H | 61d |
| 18889046 | METHOD FOR PREVENTING OR TREATING MUSCLE DISEASE | DURYEE, ALEXANDER MARSH | — |
| 18270078 | TRANSFORMED HUMAN HEPATIC STELLATE CELL LINE AND USE THEREOF | MIANO, JOSEPH PAUL | — |
| 18837056 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | SINGH, ANOOP KUMAR | — |
| 18290668 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME | NATARAJAN, MEERA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1658 | 2 |
| 1657 | 1 |
| 1632 | 1 |
| 1643 | 1 |
| 1618 | 1 |
| 1635 | 1 |
| 1681 | 1 |
| 1652 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18889046 | METHOD FOR PREVENTING OR TREATING MUSCLE DISEASE | DURYEE, ALEXANDER MARSH | 1657 | §112 | Final Rejection | — | Pending | Sep 18, 2024 |
| 18270078 | TRANSFORMED HUMAN HEPATIC STELLATE CELL LINE AND USE THEREOF | MIANO, JOSEPH PAUL | 1631 | §102§103§112 | Non-Final OA | — | Pending | Aug 19, 2024 |
| 18837056 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | SINGH, ANOOP KUMAR | 1632 | §102§103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18290668 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME | NATARAJAN, MEERA | 1643 | §102 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18289333 | COMPLEX FOR BIOIMAGING, AND DIAGNOSIS OR TREATMENT OF CANCER | BAEK, JONGHWAN NMN | 1618 | §103 | Final Rejection | — | Pending | Nov 02, 2023 |
| 18283589 | COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL | KONOPKA, CATHERINE ANNE | 1635 | §103§112Other | Non-Final OA | 7d | Pending | Sep 22, 2023 |
| 18282160 | NOVEL BICYCLIC COMPOUND, OPTICAL ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USE THEREOF, AND PREPARATION METHOD THEREFOR | REYNOLDS, FRED H | 1658 | §101 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18037222 | COMPOSITION FOR DETECTING TARGET NUCLEIC ACID AND METHOD FOR DETECTING TARGET NUCLEIC ACID USING SAME | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103§112 | Non-Final OA | — | Pending | May 16, 2023 |
| 18312110 | NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS | REYNOLDS, FRED H | 1658 | §101§102§103 | Final Rejection | 61d | Pending | May 04, 2023 |
| 17767425 | MONO-HYDROXY OR DI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS, PRODUCTION METHOD THEREFOR, AND USE THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102DP | Final Rejection | 45d overdue | Pending | Apr 07, 2022 |
| 17609871 | METHOD AND COMPOSITION FOR DETECTING THYROID CANCER-SPECIFIC DNA METHYLATION BIOMARKER FOR DIAGNOSIS OF THYROID CANCER | TURPIN, ZACHARY MARK | 1682 | §101§102§112 | Non-Final OA | — | Pending | Nov 09, 2021 |
| 17598916 | METHOD FOR PRODUCING CAR GENE-INTRODUCED NK CELLS AND USE THEREOF | ZHU, JIANJIAN | 1631 | §112Other | Non-Final OA | 9d | Pending | Sep 28, 2021 |
| 17231278 | HUMAN INTESTINAL EPITHELIUM MODEL AND METHOD FOR PREPARING SAME | MIANO, JOSEPH PAUL | 1631 | §103 | Final Rejection | 16d overdue | Pending | Apr 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKorea Research Institute of Bioscience and Biotechnology has 13 pending office actions as of October 2026, spread across 10 art units and 11 examiners.
Joseph Paul Miano has the most, with 2 of Korea Research Institute of Bioscience and Biotechnology's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
